Skov, V, Pedersen, R K, Andersen, M, Knudsen, T A, Sajid, Z, Gudmand-Hoeyer, J, M.J.B. Dam, M J B, Kjær, L, Ellervik, C, Larsen, T S, Lund Hansen, D, Hasselbalch, H C & Ottesen, J T 2019, ' DATA-DRIVEN ANALYSIS OF JAK2V617F KINETICS DURING INTERFERON-ALPHA2 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA AND RELATED NEOPLASMS ', 24th European Hematology Association Congress (EHA), Amsterdam, Holland, 13/06/2019-16/06/2019 . < https://library.ehaweb.org/eha/2019/24th/267055/vibe.skov.data-driven.analysis.of.jak2v617f.kinetics.during.interferon-alpha2.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1 >
Andersen Patel, D, Knudsen, T A, Lund Hansen, D, Ocias, L F, Weiss Bjerrum, O, Brabrand, M, Ellervik, C, el Fassi, D, Frederiksen, M, Kjær, L, Kielsgaard Kristensen, T, Kruse, T A, Mourits-Andersen, H T, Møller, P, Overgaard, U M, Severinsen, M T, Skov, V, Lindholm Sørensen, A, Jesper, S, Starklint, J, de Stricker, K, Thomassen, M, Larsen, T S & Hasselbalch, H C 2019, ' IMPACT OF SMOKING ON JAK2V617F ALLELE BURDEN AMONG PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS TREATED WITH PEGYLATED INTERFERON ALPHA-2 OR HYDROXYUREA IN THE DALIAH TRIAL ', HemaSphere, vol. 2019, PB2210 . < https://library.ehaweb.org/eha/2019/24th/268120/dustin.patel.impact.of.smoking.on.jak2v617f.allele.burden.among.patients.with.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dpatel >
Gigoux, M, Zappasodi, R, Park, J J, Pourpe, S, Ghosh, A, Bozkus, C C, Mangarin, L M B, Redmond, D, Svena Verma, S, Sara Schad, S, Duke, W, Leventhal, M, Jan, M, Ho, V, Hobbs, G, Knudsen, T A, Skov, V, Kjær, L, Larsen, T S, Lund Hansen, D, Coleman Lindsley, R, Hasselbalch, H C, Grauslund, J H, Mads H Andersen, M H, Holmström, M O, Chan, T, Rampal, R, Abdel-Wahab, O, Nina Bhardwaj, N, Wolchok, J D, Mullally, A & Merghoub, T 2020, ' Heteroclitic peptide cancer vaccine counters MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms ', Journal of Immunology, vol. 204, no. Suppl. 1, 239.34 . < https://www.jimmunol.org/content/204/1_Supplement/239.34 >
Knudsen, T A, Lund Hansen, D, Ocias, L F, Weiss Bjerrum, O, El Fassi, D, Frederiksen, M, Kjær, L, Kielsgaard Kristensen, T, Kruse, T A, Mourits-Andersen, H T, Møller, P, Overgaard, U M, Severinsen, M T, Skov, V H, Stentoft, J, Starklint, J, de Stricker, K, Thomassen, M, Larsen, T S & Hasselbalch, H C 2018, ' Interim analysis of the Daliah trial-a randomized controlled phase iii clinical trial Comparing recombinant interferon alpha-2 vs. Hydroxyurea in MPN patients. ', European Hematology Association 23rd congress EHA 2018, Stockholm, Sweden, 14/06/2018-17/06/2018 .
Mikkelsen, S U, Kjær, L, Bjørn, M E, Knudsen, T A, Sørensen, A L, Skov, V, Andersen, C B L, Weiss Bjerrum, O, Brochmann Mortensen, N, El Fassi, D, Kruse, T A, Larsen, T S, Mourits-Andersen, H T, Nielsen, C H, Pallisgaard, N, Thomassen, M & Hasselbalch, H C 2018, ' Safety And Efficacy Of Combination Therapy Of Interferon Αlpha-2 And Ruxolitinib In Polycythemia Vera And Low-/Intermediate-1-Risk Myelofibrosis – A One Year Follow-Up Update Of A Phase II Study ', European Hematology Association 23rd congress EHA 2018, Stockholm, Sweden, 14/06/2018-17/06/2018 . Mikkelsen, S U, Kjær, L, Bjørn, M E, Knudsen, T A, Sørensen, A L, Skov, V, Andersen, C B L, Weiss Bjerrum, O, Brochmann Mortensen, N, El Fassi, D, Kruse, T A, Larsen, T S, Mourits-Andersen, H T, Nielsen, C H, Pallisgaard, N, Thomassen, M & Hasselbalch, H C 2018, ' SAFETY AND EFFICACY OF COMBINATION THERAPY OF INTERFERON ΑLPHA-2 AND RUXOLITINIB IN POLYCYTHEMIA VERA AND LOW-/INTERMEDIATE-1-RISK MYELOFIBROSIS – A ONE YEAR FOLLOW-UP UPDATE OF A PHASE II STUDY ', EHA Learning Center, vol. 2018, PF620 . < http://learningcenter.ehaweb.org/eha/2018/stockholm/215880/stine.mikkelsen.safety.and.efficacy.of.combination.therapy.of.interferon.html >